This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VLON vs. WHWK, LITS, OSTX, ELYM, ATNM, AADI, NBRV, EGRX, PYRGF, and NNVCShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Whitehawk Therapeutics (WHWK), Lite Strategy (LITS), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and NanoViricides (NNVC). Vallon Pharmaceuticals vs. Its Competitors Whitehawk Therapeutics Lite Strategy OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Eagle Pharmaceuticals PyroGenesis Canada NanoViricides Vallon Pharmaceuticals (NASDAQ:VLON) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability. Do analysts recommend VLON or WHWK? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vallon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Do insiders & institutionals hold more shares of VLON or WHWK? 8.7% of Vallon Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 37.3% of Vallon Pharmaceuticals shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, VLON or WHWK? Vallon Pharmaceuticals has a beta of -1.14, meaning that its stock price is 214% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Does the media refer more to VLON or WHWK? In the previous week, Whitehawk Therapeutics had 5 more articles in the media than Vallon Pharmaceuticals. MarketBeat recorded 5 mentions for Whitehawk Therapeutics and 0 mentions for Vallon Pharmaceuticals. Whitehawk Therapeutics' average media sentiment score of 1.10 beat Vallon Pharmaceuticals' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Vallon Pharmaceuticals Neutral Whitehawk Therapeutics Positive Is VLON or WHWK more profitable? Whitehawk Therapeutics has a net margin of 99.42% compared to Vallon Pharmaceuticals' net margin of 0.00%. Whitehawk Therapeutics' return on equity of -75.99% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vallon PharmaceuticalsN/A -230.48% -124.89% Whitehawk Therapeutics 99.42%-75.99%-68.57% Which has preferable earnings and valuation, VLON or WHWK? Vallon Pharmaceuticals has higher earnings, but lower revenue than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Vallon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVallon Pharmaceuticals$100K250.77-$7.02M-$0.78-2.38Whitehawk Therapeutics$25.98M3.66-$63.69M-$0.06-33.67 SummaryWhitehawk Therapeutics beats Vallon Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VLON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.08M$791.27M$6.10B$10.63BDividend YieldN/A4.84%5.67%4.71%P/E Ratio-2.381.3085.2726.57Price / Sales250.7729.35612.78132.63Price / CashN/A17.6438.5062.09Price / Book10.337.3112.726.53Net Income-$7.02M-$7.96M$3.30B$275.96M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$1.86-5.6%N/A+358.1%$25.08M$100K-2.383WHWKWhitehawk Therapeutics0.9896 of 5 stars$1.91+0.5%N/AN/A$89.54M$25.98M-31.8321News CoveragePositive NewsAnalyst UpgradeGap DownLITSLite StrategyN/A$2.56+5.8%N/AN/A$86.29M$65.30M0.00100News CoverageAnalyst ForecastGap UpOSTXOS TherapiesN/A$2.00+2.0%$18.00+800.0%N/A$63.29MN/A-2.53N/AELYMEliem TherapeuticsN/A$2.01+1.0%N/A-65.1%$59.80MN/A-3.799ATNMActinium Pharmaceuticals1.8663 of 5 stars$1.60flat$4.50+181.3%-8.6%$49.91MN/A-1.1530AADIAadi BioscienceN/A$1.90-1.0%N/A+9.0%$46.92M$25.07M-0.8340NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle Pharmaceuticals1.3471 of 5 stars$2.70flatN/A+166.7%$35.07M$257.55M0.00100Gap DownPYRGFPyroGenesis CanadaN/A$0.16-5.2%N/A-69.2%$30.23M$9.14M-2.6990Gap DownHigh Trading VolumeNNVCNanoViricides0.0887 of 5 stars$1.44+0.7%N/A+0.0%$23.14MN/A-2.0020 Related Companies and Tools Related Companies WHWK Alternatives LITS Alternatives OSTX Alternatives ELYM Alternatives ATNM Alternatives AADI Alternatives NBRV Alternatives EGRX Alternatives PYRGF Alternatives NNVC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VLON) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
